article thumbnail

Case study: NCI’s Molecular Targets Platform

The Open Targets Blog

  However, the complexity of the system requires a lot of domain knowledge and software engineering experience, and the major challenge for us sits on the data side: it is challenging to ensure the data, configuration settings, or scripts we are using are updated at the same time as the Open Targets Platform.

article thumbnail

Study finds new therapeutic targets for neurodegenerative disease

Drug Discovery World

In this study, the researchers combined Insilico’s artificial intelligence (AI)-driven target identification engine PandaOmics with the FuzDrop method for predicting protein separation to identify PPS-prone disease-associated proteins.

Disease 174
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Improving viral vector safety for gene therapies

Drug Discovery World

The composition of engineered cells in vivo can change over time as clones proliferate at varying rates. Integrating vectors such as lentivirus stably insert their payload into the host cell genome, which is advantageous for long-term treatment.

Therapies 148
article thumbnail

Start-up hopes to boost production of viral vectors for ATMPs

Drug Discovery World

New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies.

article thumbnail

Drug discovery’s senior appointments for Q4

Drug Discovery World

Organ-on-a-chip company CN Bio has appointed Neil Rumbelow as Director of Product Development, and who joins CN Bio from Owlstone Medical where he was Head of Engineering. Professor Charlotte Deane MBE is the new Executive Chair of the Engineering & Physical Sciences Research Council (EPSRC).

article thumbnail

Drug discovery deals highlight key growth areas

Drug Discovery World

GenomeFrontier will use their virus-free cell and gene engineering platforms and Quantum Engine cell-engineering system to manufacture the CAR-T therapy for use in a Phase I clinical trial. BioCina will provide process development and GMP manufacturing for Minicircle DNA and Plasmid DNA.

DNA 130
article thumbnail

Not all neoantigens are created equal

Drug Target Review

Recent advances in bioinformatics show clonal neoantigens are the best targets for immunotherapy, as I will elucidate below. Using powerful bioinformatics technology developed and validated with sequence data from the TRACERx study, researchers are able to identify clonal neoantigens from a patient’s unique tumour profile.